Know what your asset is worth, and what a partner will actually pay for it.
We help biotech, medtech, and diagnostics leaders make the decisions that determine company value: which programs to fund, when to partner, and what terms to hold out for.
Pillars
Why Leaders Bring Us Their Hardest Decisions
I
Decision-Science Lineage
Trained at Stanford University and Strategic Decisions Group, the practice that pioneered probabilistic asset valuation for the pharmaceutical industry.
II
Proprietary Deal-Terms Data
Deal terms benchmarked against real, unredacted transaction data, accounting for asset value and strength of negotiating position.
III
A Proven Track Record
More than 20 closed transactions, partnerships, M&A, and financings, personally negotiated
IV
An Operator's Perspective
Six years in biotech leadership, on the client's side of the table.
Services
Case studies
Powerful Work that
Drives Results
Our approach
From an open question to a decision you can defend.
Diagnose the Decision
1
We start by understanding exactly what's being decided: an asset's value, a partnering choice, a portfolio call, and what's driving the timeline.
Build the Case
2
Win the Room
3
Testimonials
What Clients Say
"I've hired Michael six times, across five companies over 20 years, public and private. There's a reason: when a valuation or a set of deal terms has to hold up, to a board, to an investor, to the other side of the table, his analysis is the one I trust."
Stephen Worsley
Managing Director, Miramonte Capital Advisors
"Michael is who you bring in when the C-suite and the board need to converge on a hard portfolio or strategy call. He builds the analysis that gets everyone aligned on a path forward. We hired him four times across two public companies at key strategic moments."
Chief Business Officer
public clinical-stage biotech
"Michael was our advisor on two drug candidates, and we closed partnership deals on both. Then I hired him; that's how much I trusted the work. Across everything we've done together, four closed partnerships and two financings, his valuation analysis got deals done."
Chris Rivera
CEO, Hyperion Therapeutics
Twice now we've brought Michael in at the stage where a diagnostics company lives or dies on its story to investors. Both times he built on our technology story to help develop P&L projections and valuation that held up to due diligence."
Dave Beebe
Chief Scientific Officer
"Asset valuation, market research, revenue forecasting, BD strategy. Michael does the quantitative work at a level most consultants only talk about."
Mark F. Kubik
Chief Business Officer
Three engagements, three different companies, therapeutics and diagnostics, and each time the same result: analytics that gave us the edge with investors and acquirers."
Steve Brauer
CEO/VC
Questions & answers
Frequently
Asked Questions
How do I know which service is the best fit for my situation?
Most clients don't arrive asking for a service; they arrive with a decision. A partnering offer on the table. A portfolio that outruns the cash. A board that wants a number it can defend. Tell us what you're deciding and when, and we'll tell you what the work should be. If the answer is a two-week valuation rather than a three-month strategy engagement, we'll say so.